ABSTRACT
Hypertrophic cardiomyopathy (HCM) is a genetic cardiovascular disease caused by mutations in genes that encode components of the sarcomere. Standard echocardiography is not always capable to identify regional systolic dysfunction of the left ventricle (LV), and to detect the disease on its preclinical stage. Genetic testing allows identifying sarcomere gene mutations in less than 50% of patients due to difficulty of screening all genes responsible for hypertrophic cardiomyopathy. Modern innovative methods of echocardiography - tissue Doppler, strain and strain rate, speckle tracking have been widely used for quantification of regional ventricular motion. Work of recent decades has proven the ability of these techniques to detect regional systolic and diastolic dysfunction of the LV, to diagnose HCM early, to differentiate it from other pathological and physiological hypertrophies. These modes can be used for prediction of cardiovascular complications in patients with HCM. In clinical practice the use of innovative technologies in combination with standard echocardiography allows to obtain more accurate and extensive information on the severity and prognosis of the disease.
Subject(s)
Cardiomyopathy, Hypertrophic, Familial , Echocardiography, Doppler/methods , Myocardium/pathology , Ventricular Dysfunction, Left/diagnosis , Cardiomyopathy, Hypertrophic, Familial/diagnosis , Cardiomyopathy, Hypertrophic, Familial/genetics , Cardiomyopathy, Hypertrophic, Familial/physiopathology , Genetic Testing , Genome-Wide Association Study , Humans , Myocardial Contraction , Ventricular Dysfunction, Left/etiologyABSTRACT
The paper describes a clinical case of the efficacy of a fixed-dose combination of perindopril and amlodipine used in a hypertensive patient. It shows its clinical effectiveness with no impact on blood lipid and glucose levels. 24-hour blood pressure monitoring revealed a reduction in daily blood pressure, including its variability, in pulse wave propagation velocity and central aortic pressure.
